These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 16523315)

  • 21. Cardiovascular manifestations of insulin resistance.
    Chahwala V; Arora R
    Am J Ther; 2009; 16(5):e14-28. PubMed ID: 19114874
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Tight glycemic control in the management of diabetic patients: what has changed since the '90s in the clinical approach?].
    Fiorentino TV; Sesti G
    G Ital Cardiol (Rome); 2014 Dec; 15(12 Suppl 2):13S-20S. PubMed ID: 25623546
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Are Diabetes Care Providers Too Glucocentric?
    Lau DC
    Can J Diabetes; 2016 Dec; 40(6):479-481. PubMed ID: 27810227
    [No Abstract]   [Full Text] [Related]  

  • 24. Cardiovascular risk in the spectrum of type 2 diabetes mellitus.
    Ahmed I; Goldstein BJ
    Mt Sinai J Med; 2006 Sep; 73(5):759-68. PubMed ID: 17008936
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Survey of trends and gaps in dermatologists' cardiovascular screening practices in psoriasis patients: Areas still in need of improvement.
    Manalo IF; Gilbert KE; Wu JJ
    J Am Acad Dermatol; 2015 Nov; 73(5):872-4.e4. PubMed ID: 26475543
    [No Abstract]   [Full Text] [Related]  

  • 26. Treating the diabetic patient: appropriate care for glycemic control and cardiovascular disease risk factors.
    Zarich SW
    Rev Cardiovasc Med; 2003; 4 Suppl 6():S19-28. PubMed ID: 14668700
    [TBL] [Abstract][Full Text] [Related]  

  • 27. For the majority of patients with diabetes blood pressure and lipid management is not in line with recommendations. Results from a large population-based cohort in Germany.
    Raum E; Lietzau S; Stegmaier C; Brenner H; Rothenbacher D
    Pharmacoepidemiol Drug Saf; 2008 May; 17(5):485-94. PubMed ID: 18383562
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Type 2 diabetes among women: clinical considerations for pharmacological management to achieve glycemic control and reduce cardiovascular risk.
    Levine JP
    J Womens Health (Larchmt); 2008 Mar; 17(2):249-60. PubMed ID: 18321176
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The gap between the current dyslipidemia guidelines and the physicians' treatment targets in patients with type 2 diabetes in Turkey.
    Kahya Eren N; Harman E; Dolek D; Emren S; Tütüncüoğlu AP; Nazli C; Ergene O
    Minerva Cardioangiol; 2014 Jun; 62(3):287-95. PubMed ID: 24831765
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The significance of plasma adrenomedullin and calcitonin gene-related peptide concentration in patients with Type 2 diabetes mellitus who are treated for cardiovascular risk factors.
    Charvat J; Svab P; Havlin J; Bilek R; Zamrazil V
    Neuro Endocrinol Lett; 2014; 35(2):154-8. PubMed ID: 24878981
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical trial of the month. The STENO-2 study: a plea for global and intensive management of the type 2 diabetic patient].
    Scheen AJ; Estrella F
    Rev Med Liege; 2003 Feb; 58(2):109-11. PubMed ID: 12693313
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Cardiovascular event in elderly patients with diabetes mellitus].
    Nomura K
    Nihon Rinsho; 2013 Nov; 71(11):1954-9. PubMed ID: 24397165
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Office and ambulatory pulse pressure--association with clinical characteristics and cardiovascular risk factors in normoalbuminuric patients with type 2 diabetes (ROADMAP study).
    Januszewicz A; Ritz E; Viberti G; Mimran A; Rabelink AJ; Rump LC; Ruilope LM; Katayama S; Ito S; Izzo JL; Haller H
    J Hum Hypertens; 2011 Nov; 25(11):679-85. PubMed ID: 21150933
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current antihyperglycemic treatment strategies for patients with type 2 diabetes mellitus.
    Blonde L
    Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S4-11. PubMed ID: 19952303
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Approaches to treatment 1: How is type 2 diabetes actually treated?
    Bloomgarden ZT
    J Diabetes; 2015 Nov; 7(6):747-8. PubMed ID: 26211568
    [No Abstract]   [Full Text] [Related]  

  • 36. [Prevention of cardiovascular disease in type 2 diabetic patients].
    Yokota C
    Nihon Rinsho; 2003 Jul; 61(7):1161-6. PubMed ID: 12877078
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Should patients with type 2 diabetes focus on glycemic control to reduce their cardiovascular risk?
    Montori VM
    Pol Arch Med Wewn; 2008 Sep; 118(9):502-7. PubMed ID: 18846985
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Cardiovascular prevention in diabetes mellitus: A multifactorial challenge].
    Pedro-Botet J; Chillarón JJ; Benaiges D; Flores-Le Roux JA
    Clin Investig Arterioscler; 2016; 28(3):154-63. PubMed ID: 26655375
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus.
    Cavender MA; Lincoff AM
    Am J Cardiovasc Drugs; 2010; 10(4):209-16. PubMed ID: 20653327
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Guidelines for the management of atherosclerotic diseases in diabetes mellitus].
    Kotake H; Oikawa S
    Nihon Rinsho; 2006 Nov; 64(11):2074-80. PubMed ID: 17087299
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.